• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Brexpiprazole Intermediate CAS:70500-72-0
Brexpiprazole CAS:913611-97-9
3-BROMOPHENANTHRENE
2-FLUORO-4-(TRIFLUOROMETHYL)BENZOPHENONE
3-BROMO-4-FLUOROBIPHENYL
9-TRIFLUOROACETYLANTHRACENE

Argentina Formally Starts Producing Russia’s Sputnik Covid-19 Vaccine

firstwordpharmaJune 07, 2021

Tag: COVID-19 , Vaccine , Sputnik V

Argentina and Russia's president formally announced that a pharmaceutical company in the South American nation will start producing the Sputnik V COVID-19 vaccine, Bloomberg reported.

Argentina Formally Starts Producing Russia’s Sputnik Covid-19 Vaccine

Presidents Vladimir Putin and Alberto Fernandez said production will start at Laboratorios Richmond SA in Buenos Aires.

Argentina has received 8.9 million Sputnik V doses this year, accounting for nearly half of its total vaccines.

Previous:Phase II clinical trial of Niclosamide drug for treatment of COVID-19 patients begins

Next:South Korea's IP laws key to expanding COVID-19 vaccine partnership: US senators

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Argentina Formally Starts Producing Russia’s Sputnik Covid-19 Vaccine | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

Influenza Vaccine(Split Virion),Inactivated by Hualan Bio

Influenza Vaccine(Split Virion),Inactivated by Hualan Bio
Haemophilus Influenza Type B Conjugate Vaccine

Haemophilus Influenza Type B Conjugate Vaccine
Real Time Multiplex RT-PCR Kit (for COVID-19)

Real Time Multiplex RT-PCR Kit (for COVID-19)
Hualan bio Influenza A (H1N1) Vaccine, (Split, Inactivated)by Hualan biological

Hualan bio Influenza A (H1N1) Vaccine, (Split, Inactivated)by Hualan biological
Influenza Vaccine(Split Virion),Inactivated

Influenza Vaccine(Split Virion),Inactivated
Group ACYW135 Meningococcal Polysaccharide Vaccine with lower adverse effect

Group ACYW135 Meningococcal Polysaccharide Vaccine with lower adverse effect
High-quality Influenza Vaccine (Split virion), inactivated

High-quality Influenza Vaccine (Split virion), inactivated
Influenza Vaccine in Syringe

Influenza Vaccine in Syringe
Hualan's Influenza Vaccine

Hualan's Influenza Vaccine
Hualan Influenza Vaccine (Split virion)

Hualan Influenza Vaccine (Split virion)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service